repp86 expression and outcome in patients with neuroblastoma

Journal of Clinical Oncology

Volumn 21, Issue 9, 2003, Pages 1810-1818

  Krams, Matthias ^a   Heidebrecht, Hans Juergen ^a   Hero, Barbara ^a   Berthold, Frank ^a   Harms, Dieter ^a   Parwaresch, Reza ^a   Rudolph, Pierre ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI S2; MYC PROTEIN; PARAFFIN; PROTEIN REPP86; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE NUMBER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOLECULAR WEIGHT; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOUTHERN BLOTTING; TUMOR CELL; ADOLESCENT; BIOSYNTHESIS; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; INFANT; MALE; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; BLOTTING, SOUTHERN; CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; MALE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0038134992     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.076     Document Type: Article

References (50)

1. Maris JM, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol 17:2264-2279, 1999
2. Hughes M, Marsden HB, Palmer MK: Histologic patterns of neuroblastoma related to prognosis and clinical staging. Cancer 34:1706-1711, 1974
3. Chatten J, Shimada H, Sather HN, et al: Prognostic value of histopathology in advanced neuroblastoma: A report from the Children's Cancer Study Group. Hum Pathol 19:1187-1198, 1988
4. Joshi VV, Cantor AB, Altshuler G, et al: Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas: A clinicopathologic study of 211 cases from the Pediatric Oncology Group. Cancer 69:2197-2211, 1992
5. Shimada H, Ambros IM, Dehner LP, et al: Terminology and morphologic criteria of neuroblastic tumors: Recommendations by the International Neuroblastoma Pathology Committee. Cancer 86:349-363, 1999
6. Shimada H, Ambros IM, Dehner LP, et al: The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364-372, 1999
7. Versteeg R, Caron H, Cheng NC, et al: 1p36: Every band a suppressor? Eur J Cancer 31A:538-542, 1995
8. Brodeur GM, Seeger RC: Gene amplification in human neuroblastomas: Basic mechanisms and clinical implications. Cancer Genet Cytogenet 19:101-111, 1986
9. Schwab M: Amplification of N-myc as a prognostic marker for patients with neuroblastoma. Semin Cancer Biol 4:13-18, 1993
10. Erttmann R, Tafese T, Berthold F, et al: 10 years' neuroblastoma screening in Europe: Preliminary results of a clinical and biological review from the Study Group for Evaluation of Neuroblastoma Screening in Europe (SENSE). Eur J Cancer 34:1391-1397, 1998
11. Gallego S, Parareda A, Munell F, et al: Clinical relevance of molecular markers in neuroblastoma: Results from a single institution. Oncol Rep 6:891-896, 1999
12. Perez CA, Matthay KK, Atkinson JB, et al: Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A children's cancer group study. J Clin Oncol 18:18-26, 2000
13. Chan HS, Gallie BL, DeBoer G, et al: MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 3:1699-1706, 1997
14. Krams M, Hero B, Berthold F, et al: Proliferation marker Ki-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Cancer 94:854-861, 2002
15. Bown N, Cotterill S, Lastowska M, et al: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340:1954-1961, 1999
16. Guo C, White PS, Hogarty MD, et al: Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med Pediatr Oncol 35:544-556, 2000
17. Poremba C, Scheel C, Hero B, et al: Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: A molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol 18:2582-2592, 2000
18. Shay JW, Werbin H, Wright WE: Telomerase assays in the diagnosis and prognosis of cancer. Ciba Found Symp 211:148-155, 1997
19. Hiyama E, Hiyama K, Yokoyama T, et al: Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1:249-255, 1995
20. Brinkschmidt C, Poremba C, Christiansen H, et al: Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. Br J Cancer 77:2223-2229, 1998
21. Streutker CJ, Thorner P, Fabricius N, et al: Telomerase activity as a prognostic factor in neuroblastomas. Pediatr Dev Pathol 4:62-67, 2001
22. Krams M, Claviez A, Heidorn K, et al: Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas. Am J Pathol 159:1925-1932, 2001
23. Krupp G, Klapper W, Parwaresch R: Cell proliferation, carcinogenesis and diverse mechanisms of telomerase regulation. Cell Mol Life Sci 57:464-486, 2000
24. 2, and M. Blood 90:226-233, 1997
25. Heidebrecht HJ, Adam-Kages S, Szczepanowski M, et al: repp86: A human protein associated in the progression of mitosis. Mol Cancer Res 1:271-279, 2003
26. Wittmann T, Wilm M, Karsenti E, et al: TPX2, A novel xenopus MAP involved in spindle pole organization. J Cell Biol 149:1405-1418, 2000
27. Gruss OJ, Carazo-Salas RE, Schatz CA, et al: Ran induces spindle assembly by reversing the inhibitory effect of importin alpha on TPX2 activity. Cell 104:83-93, 2001
28. Rudolph P, Knüchel R, Endl E, et al: The immunohistochemical marker Ki-S2: Tissue distribution and cell cycle kinetics of a novel proliferation-specific antigen. Mod Pathol 11:450-456, 1998
29. Rudolph P, Aim P, Olsson H, et al: Concurrent overexpression of p53 and erbB2 correlates with accelerated cycling and concomitant poor prognosis in lymph node-negative breast cancer. Hum Pathol 32:311-319, 2001
30. Rudolph P, Schubert C, Tamm S, et al: Telomerase activity in melanocytic lesions: A potential marker of tumor biology. Am J Pathol 156:1425-1437, 2000
31. Bonatz G, Frahm SO, Klapper W, et al: High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid adenocarcinoma of the uterus. Hum Pathol 32:605-614, 2001
32. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
33. Berthold F, Sahin K, Hero B, et al: The current contribution of molecular factors to risk estimation in neuroblastoma patients. Eur J Cancer 33:2092-2097, 1997
34. Stout AP: Ganglioneuroma of the sympathetic system. Surg Gynecol Obstet 84:101-110, 1947
35. Schmidt D, Harms D, Carstensen S: Ganglioneuroblastom-Diagnose und Verlauf. Verh Dtsch Ges Pathol 72:292-295, 1988
36. Cordell JL, Falini B, Erber WN, et al: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219-229, 1984
37. Hiyama E, Hiyama K, Yokoyama T, et al: Length of telomeric repeats in neuroblastoma: Correlation with prognosis and other biological characteristics. Jpn J Cancer Res 83:159-164, 1992
38. Shapiro DN, Valentine MB, Rowe ST, et al: Detection of N-myc gene amplification by fluorescence in situ hybridization: Diagnostic utility for neuroblastoma. Am J Pathol 142:1339-1346, 1993
39. Rudolph P, Alm P, Heidebrecht H-J, et al: Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst 91:271-278, 1999
40. Parwaresch R, Rudolph P: The cell cycle: Theory and applications to cancer. Onkologie 19:464-472, 1996
41. Shimada H, Chatten J, Newton WAJ, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405-416, 1984
42. Joshi VV, Chatten J, Sather HN, et al: Evaluation of the Shimada classification in advanced neuroblastoma with a special reference to the mitosis-karyorrhexis index: A report from the Children's Cancer Study Group. Mod Pathol 4:139-147, 1991
43. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984
44. Schwarting R: Little missed markers and Ki-67. Lab Invest 68:597-599, 1993
45. Rudolph P, Lappe T, Hero B, et al: Prognostic significance of the proliferative activity in neuroblastoma. Am J Pathol 150:133-145, 1997
46. Baserga R, Porcu P, Sell C: Oncogenes, growth factors and control of the cell cycle. Cancer Surv 16:201-213, 1993
47. van Noesel MM, Hahlen K, Hakvoort-Cammel FG, et al: Neuroblastoma 4S: A heterogeneous disease with variable risk factors and treatment strategies. Cancer 80:834-843, 1997
48. Bonatz G, Luttges J, Hedderich J, et al: Prognostic significance of a novel proliferation marker, anti-repp 86, for endometrial carcinoma: A multivariate study. Hum Pathol 30:949-956, 1999
49. Baserga R: Oncogenes and the strategy of growth factors. Cell 79:927-930, 1994
50. Krupp G, Bonatz G, Parwaresch R: Telomerase, immortality and cancer. Biotechnol Annu Rev 6:103-140, 2000